A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Eocene Ltd. a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Eocene Ltd. was formerly known as Galmed Pharmaceuticals Ltd. and changed its name to Eocene Ltd. in September 2026. Eocene Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Financial Summary
| Share Statistics | EOCN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3.8 | $269.3 | 2% |
|
| Shares Out (Mil) | 1.0 | 54.0 | 4% |
|
| Institutional Ownership | 62.0% | 93.0% | 39% |
|
| Float (Mil) | 1.0 | 42.2 | 2% |
|
| Beta | 0.67 | 0.95 | 39% |
|
| Avg Daily Volume (000s) | 62 | 473 | 31% |
|
| Price Change (52-week) |
(66.0%) | 55.9% | 11% |
|
| Growth | EOCN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | 18.6% | (10.1%) | 71% |
|
| EPS (5yr) | na | 15.7% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 71.1% | (15.6%) | 97% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | EOCN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($11) | ($43) | 28% |
|
| EPS (TTM) | ($14.106) | ($1.500) | 4% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($31) | 21% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($7) | $182 | 2% |
|
| Valuation | EOCN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.30 | 2.62 | 4% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | EOCN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (73.5%) | na |
|
| ROA | (55.0%) | (47.9%) | 11% |
|
| ROE | (68.2%) | (55.0%) | 12% |
|
| Liabilities to Assets | 30.3% | 29.5% | 22% |
|
| F-Score | na | 3 | % |
|
Eocene Ltd. did not pass any screens on 9/11/2026.
